The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...
Biohaven (NYSE:BHVN) shares traded higher on Wednesday after the company said its antibody-drug conjugate BHV-1510 with cemiplimab, an anti-PD-1 therapy marketed by Regeneron (NASDAQ:REGN) as Libtayo, ...
Merck (NYSE:MRK) announced Tuesday that the European Commission approved its anti-cancer agent Welireg (belzutifan) as a treatment for two tumor conditions linked to kidneys. Accordingly, the oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results